Publications by authors named "Fanli Zheng"

Claim this Profile
N
Novel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.
Enjun Zhang, Jun Lu, Liying Liu, Lunming Liu, Hongtao Hu, Fanli Zheng

Med Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
Ya-Nan Zheng, Si-Yue Lou, Jun Lu, Fan-Li Zheng, Yong-Mei Tang

Cell Death Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
Si-Yue Lou, Fan-Li Zheng, Yong-Mei Tang, Ya-Nan Zheng, Jun Lu

Life Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.
Yongmei Tang, Fanli Zheng, Xiaodong Bao, Yanan Zheng, Xueping Hu

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydnocarpin D attenuates lipopolysaccharide-induced acute lung injury via MAPK/NF-κB and Keap1/Nrf2/HO-1 pathway.
Huanwu Hong, Siyue Lou, Fanli Zheng, Hang Gao, Nina Wang, Guozheng Huang

Phytomedicine· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis